報價延遲最少15分鐘:2026/04/23 23:54 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.74 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.38/-0.44
|
|
企業價值
250.95M
|
| 資產負債 |
|
每股賬面淨值
0.54
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
7.67M
|
|
每股收益
0.34
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies. |
